The year is a transition and recalibration year, marked by policy articulation, institutional repositioning, improved ...
The FDA's December 22, 2025 approval expanded GLP-1 access beyond injectable formulations by adding an oral semaglutide option for chronic weight management, based on FDA-reviewed labeling and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback